<p>毫无疑问，通过持有不盈利企业的股票可以赚钱。例如，尽管亚马逊在上市后的许多年里都在亏损，但如果你从 1999 年开始购买并持有其股票，你将赚得盆满钵满。但历史虽然赞美那些罕见的成功案例，但失败的案例往往被遗忘；谁还记得 Pets.com？</p>
<p>鉴于这种风险，我们认为有必要看看 <strong>Cocrystal Pharma</strong> (NASDAQ:COCP) 的股东是否应该担心其现金消耗。为了本文的目的，我们将现金消耗定义为公司每年用于资助其增长的现金支出（也称为负自由现金流）。第一步是将其现金消耗与现金储备进行比较，以便得出其 “现金跑道”。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<h2>Cocrystal Pharma 何时可能耗尽资金？</h2>
<p>公司的现金跑道是指以当前现金消耗率耗尽现金储备所需的时间。到 2025 年 12 月，Cocrystal Pharma 拥有 700 万美元的现金，并且没有债务。重要的是，其过去 12 个月的现金消耗为 820 万美元。因此，从 2025 年 12 月起，它大约有 10 个月的现金跑道。坦率地说，这种短暂的跑道让我们感到不安，因为这表明公司必须显著减少现金消耗，否则就必须立即筹集资金。下图显示了其现金余额在过去几年的变化情况。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/49062639-debt-equity-history-analysis-1-dark-2/1775304095002?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/49062639-debt-equity-history-analysis-1-dark-2/1775304095002"/></p>
<p>NasdaqCM:COCP2026 年 4 月 4 日的债务与股本历史</p>
<p>查看我们对 Cocrystal Pharma 的最新分析</p>
<h2>Cocrystal Pharma 的现金消耗随时间变化情况如何？</h2>
<p>Cocrystal Pharma 在过去一年没有记录任何收入，这表明它仍是一家处于早期阶段的公司，仍在发展其业务。因此，虽然我们无法通过销售来理解增长，但我们可以通过观察现金消耗的变化来了解支出随时间的趋势。实际上，该公司的现金消耗在过去一年减少了 50%，这表明管理层意识到耗尽现金的可能性。虽然过去值得研究，但未来才是最重要的。因此，查看我们对该公司的分析师预测是非常有意义的。</p>
<h2>Cocrystal Pharma 多容易筹集资金？</h2>
<p>毫无疑问，Cocrystal Pharma 快速减少的现金消耗让人感到宽慰，但即使这只是理论上的，询问它多容易筹集更多资金以资助进一步增长也是值得的。一般来说，上市公司可以通过发行股票或承担债务来筹集新资金。许多公司最终通过发行新股来资助未来的增长。我们可以将公司的现金消耗与其市值进行比较，以了解公司需要发行多少新股来资助一年的运营。</p>
<p>由于其市值为 2100 万美元，Cocrystal Pharma 的 820 万美元现金消耗约占其市值的 39%。这是一种相当显著的现金消耗，因此如果公司不得不出售股票以覆盖另一年运营的成本，股东将遭受一些昂贵的稀释。</p>
<h2>Cocrystal Pharma 的现金消耗情况有多风险？</h2>
<p>尽管其现金消耗相对于市值让我们有些紧张，但我们不得不提到，我们认为 Cocrystal Pharma 的现金消耗减少相对令人鼓舞。考虑到本短报告中提到的因素，我们确实认为其现金消耗有些风险，这让我们对该股票感到稍微紧张。另一方面，Cocrystal Pharma 有 <strong>7 个警告信号</strong>（其中 4 个不可忽视），我们认为你应该了解。</p>
<p>当然，<strong>Cocrystal Pharma 可能不是最佳购买股票</strong>。因此，你可能希望查看这份 <strong>免费</strong> 的高股本回报公司集合，或这份高内部持股的股票列表。</p>
<h3><strong>新：AI 股票筛选器和警报</strong></h3>
<p>我们的新 AI 股票筛选器每天扫描市场以发现机会。</p>
<p>• 股息强劲的公司（收益率 3%+）</p>
<p>• 内部人士购买的被低估小盘股</p>
<p>• 高增长的科技和 AI 公司</p>
<p>或从 50 多个指标中构建自己的筛选器。</p>
<p>立即免费探索</p>

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

<p>Cocrystal Pharma（纳斯达克代码：COCP）正面临现金消耗率的担忧，目前拥有 700 万美元的现金，而过去一年现金消耗为 820 万美元，这意味着其现金续航时间约为 10 个月。尽管公司最近将现金消耗减少了 50%，但其 2100 万美元的市值意味着现金消耗占其价值的 39%，如果发行新股，将增加股东的潜在稀释风险。总体而言，尽管现金消耗的减少令人鼓舞，但情况仍然存在风险</p>

<p>There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?</p>
<div class="lb-trans"><p>毫无疑问，通过持有不盈利企业的股票可以赚钱。例如，尽管亚马逊在上市后的许多年里都在亏损，但如果你从 1999 年开始购买并持有其股票，你将赚得盆满钵满。但历史虽然赞美那些罕见的成功案例，但失败的案例往往被遗忘；谁还记得 Pets.com？</p>
</div><p>Given this risk, we thought we'd take a look at whether <strong>Cocrystal Pharma</strong> (NASDAQ:COCP) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.</p>
<div class="lb-trans"><p>鉴于这种风险，我们认为有必要看看 <strong>Cocrystal Pharma</strong> (NASDAQ:COCP) 的股东是否应该担心其现金消耗。为了本文的目的，我们将现金消耗定义为公司每年用于资助其增长的现金支出（也称为负自由现金流）。第一步是将其现金消耗与现金储备进行比较，以便得出其 “现金跑道”。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><h2>When Might Cocrystal Pharma Run Out Of Money?</h2>
<div class="lb-trans"><h2>Cocrystal Pharma 何时可能耗尽资金？</h2>
</div><p>A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In December 2025, Cocrystal Pharma had US$7.0m in cash, and was debt-free. Importantly, its cash burn was US$8.2m over the trailing twelve months. Therefore, from December 2025 it had roughly 10 months of cash runway. To be frank, this kind of short runway puts us on edge, as it indicates the company must reduce its cash burn significantly, or else raise cash imminently. The image below shows how its cash balance has been changing over the last few years.</p>
<div class="lb-trans"><p>公司的现金跑道是指以当前现金消耗率耗尽现金储备所需的时间。到 2025 年 12 月，Cocrystal Pharma 拥有 700 万美元的现金，并且没有债务。重要的是，其过去 12 个月的现金消耗为 820 万美元。因此，从 2025 年 12 月起，它大约有 10 个月的现金跑道。坦率地说，这种短暂的跑道让我们感到不安，因为这表明公司必须显著减少现金消耗，否则就必须立即筹集资金。下图显示了其现金余额在过去几年的变化情况。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/49062639-debt-equity-history-analysis-1-dark-2/1775304095002" alt="" original-src="https://images.simplywall.st/asset/chart/49062639-debt-equity-history-analysis-1-dark-2/1775304095002"/></p>
<p>NasdaqCM:COCP Debt to Equity History April 4th 2026</p>
<div class="lb-trans"><p>NasdaqCM:COCP2026 年 4 月 4 日的债务与股本历史</p>
</div><p>Check out our latest analysis for Cocrystal Pharma</p>
<div class="lb-trans"><p>查看我们对 Cocrystal Pharma 的最新分析</p>
</div><h2>How Is Cocrystal Pharma's Cash Burn Changing Over Time?</h2>
<div class="lb-trans"><h2>Cocrystal Pharma 的现金消耗随时间变化情况如何？</h2>
</div><p>Cocrystal Pharma didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. As it happens, the company's cash burn reduced by 50% over the last year, which suggests that management are mindful of the possibility of running out of cash. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.</p>
<div class="lb-trans"><p>Cocrystal Pharma 在过去一年没有记录任何收入，这表明它仍是一家处于早期阶段的公司，仍在发展其业务。因此，虽然我们无法通过销售来理解增长，但我们可以通过观察现金消耗的变化来了解支出随时间的趋势。实际上，该公司的现金消耗在过去一年减少了 50%，这表明管理层意识到耗尽现金的可能性。虽然过去值得研究，但未来才是最重要的。因此，查看我们对该公司的分析师预测是非常有意义的。</p>
</div><h2>How Easily Can Cocrystal Pharma Raise Cash?</h2>
<div class="lb-trans"><h2>Cocrystal Pharma 多容易筹集资金？</h2>
</div><p>There's no doubt Cocrystal Pharma's rapidly reducing cash burn brings comfort, but even if it's only hypothetical, it's always worth asking how easily it could raise more money to fund further growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.</p>
<div class="lb-trans"><p>毫无疑问，Cocrystal Pharma 快速减少的现金消耗让人感到宽慰，但即使这只是理论上的，询问它多容易筹集更多资金以资助进一步增长也是值得的。一般来说，上市公司可以通过发行股票或承担债务来筹集新资金。许多公司最终通过发行新股来资助未来的增长。我们可以将公司的现金消耗与其市值进行比较，以了解公司需要发行多少新股来资助一年的运营。</p>
</div><p>Since it has a market capitalisation of US$21m, Cocrystal Pharma's US$8.2m in cash burn equates to about 39% of its market value. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's operations, shareholders would suffer some costly dilution.</p>
<div class="lb-trans"><p>由于其市值为 2100 万美元，Cocrystal Pharma 的 820 万美元现金消耗约占其市值的 39%。这是一种相当显著的现金消耗，因此如果公司不得不出售股票以覆盖另一年运营的成本，股东将遭受一些昂贵的稀释。</p>
</div><h2>How Risky Is Cocrystal Pharma's Cash Burn Situation?</h2>
<div class="lb-trans"><h2>Cocrystal Pharma 的现金消耗情况有多风险？</h2>
</div><p>Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Cocrystal Pharma's cash burn reduction was relatively promising. Looking at the factors mentioned in this short report, we do think that its cash burn is a bit risky, and it does make us slightly nervous about the stock. On another note, Cocrystal Pharma has <strong>7 warning signs</strong> (and 4 which can't be ignored) we think you should know about.</p>
<div class="lb-trans"><p>尽管其现金消耗相对于市值让我们有些紧张，但我们不得不提到，我们认为 Cocrystal Pharma 的现金消耗减少相对令人鼓舞。考虑到本短报告中提到的因素，我们确实认为其现金消耗有些风险，这让我们对该股票感到稍微紧张。另一方面，Cocrystal Pharma 有 <strong>7 个警告信号</strong>（其中 4 个不可忽视），我们认为你应该了解。</p>
</div><p>Of course <strong>Cocrystal Pharma may not be the best stock to buy</strong>. So you may wish to see this <strong>free</strong> collection of companies boasting high return on equity, or this list of stocks with high insider ownership.</p>
<div class="lb-trans"><p>当然，<strong>Cocrystal Pharma 可能不是最佳购买股票</strong>。因此，你可能希望查看这份 <strong>免费</strong> 的高股本回报公司集合，或这份高内部持股的股票列表。</p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新：AI 股票筛选器和警报</strong></h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我们的新 AI 股票筛选器每天扫描市场以发现机会。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 股息强劲的公司（收益率 3%+）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 内部人士购买的被低估小盘股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增长的科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或从 50 多个指标中构建自己的筛选器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免费探索</p>
</div>

我们正在密切关注 Cocrystal Pharma（NASDAQ:COCP）的现金消耗率